Q3 2025 Earnings Call Transcript November 4, 2025 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

Aurinia Pharmaceuticals (AUPH) has swung into profitability over the past year, with earnings climbing at an impressive 43.8% per year on average for the past five years. Investors have watched as ...

Aurinia Pharmaceuticals (AUPH) traded lower on Wednesday as RBC Capital Markets downgraded the stock, citing an uneven risk-reward profile after the biotech added over ~8% in the previous session in ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

Dr. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...

The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused ...

The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on ...